News from the Hereditary Neuropathy Foundation: research updates, clinical trial progress, partnerships, and advocacy wins for the Charcot-Marie-Tooth community.
No matches for .
Showing 61 to 72 of 153 in News
October 19, 2023
Congratulations to GRIN Advisory Board member, Professor Joshua Burns, for being recognized by the Australian Academy of Health and Medical Sciences for his outstanding contributions to medical and health sciences.
August 31, 2023
Pediatric CMT Natural History Study enhancement to their Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN) patient registry, Global Registry for Inherited Neuropathies (GRIN).
August 29, 2023
HNF is proud to present “CMT Presents,” a virtual presentation series designed to spread awareness in the communities, companies, and groups closest to you!
August 2, 2023
Dtx today announced that the FDA has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
August 2, 2023
Pharnext announces new positive results from the ongoing open-label extension study of their drug PXT3003
August 2, 2023
Applied Therapeutics, Inc. has announced that their drug candidate, AT-007 (Govorestat), has received orphan medicinal product designation
August 2, 2023
Data regarding medical cannabis use for pain relief in CMT from HNF’s CMT Patient Registry, GRIN
July 13, 2023
The study highlights the significant impact of neuropathic pain on the quality of life and psychosocial well-being of individuals with CMT.
June 13, 2023
Mitochondria are the powerhouses of our cells. Think of them as our body’s batteries. Mitochondrial disease causes these batteries to run low.
Changes how this site looks for you, and are saved on this device.
We use cookies to see how the site is used (analytics) and to power embedded videos and podcasts. Analytics stay off until you say yes. See our privacy policy.
Be the first to know
Research moves fast. Add your number and we will text you the things that matter most: new treatment news, trial openings, and ways to take part before they fill up.
